Related Experiment Video
Updated: May 5, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Biosimilars: company strategies to capture value from the biologics market
Bruno Calo-Fernández1, Juan Leonardo Martínez-Hurtado
1Escuela Técnica Superior de Ingeniería, Universidad de Santiago de Compostela, Rúa Lope Gómez de Marzoa s/n, Campus Vida 15782, Santiago de Compostela, Spain. bruno.calo@rai.usc.es.
Abstract:
Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Upstream Processing
Bioequivalence: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...